Lei Hou

Lei Hou


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2023 in Stem Cells International
Verified
Journal Article
Open access
PDF file
ZLZhenzhen Li
Zhenzhen Li
BZBeijie Zheng
Beijie Zheng
CLChenchen Liu
Chenchen Liu
XZXiang Zhao
Xiang Zhao
YZYupeng Zhao
Yupeng Zhao
ZYZhongwei Yang
Zhongwei Yang
Type II alveolar epithelial cell (AECII) apoptosis is one of the most vital causes of sepsis-induced acute respiratory distress syndrome (ARDS). Recent evidence has proved that bone mesenchymal stem cell-derived exosomes (BMSC-exos) can effectively reduce sepsis-induced ARDS. However, the function and molecular mechanism of BMSC-exos in sepsis-induced AECII apoptosis remain to be elucidated. In the present study, a more significant number of AECII apoptosis, high mitochondrial fission p-Drp1 protein levels, and low levels of mitochondrial biogenesis-related PGC1α, Tfam, and Nrf1 proteins accompanied with ATP content depression were confirmed in AECIIs in response to sepsis. Surprisingly, BMSC-exos successfully recovered mitochondrial biogenesis, including the upregulated expression of PGC1α, Tfam, Nrf1 proteins, and ATP contents, and prohibited p-Drp1-mediated mitochondrial fission by promoting Nrf2 expression. However, the aforementioned BMSC-exo reversal of mitochondrial dysfunction in AECIIs can be blocked by Nrf2 inhibitor ML385. Finally, BMSC-exos ameliorated the mortality rate, AECII apoptosis, inflammatory cytokine storm including HMGB1 and IL-6, and pathological lung damage in sepsis mice, which also could be prevented by ML385. These findings reveal a new mechanism of BMSC-exos in reversing mitochondrial dysfunction to alleviate AECII apoptosis, which may provide novel strategies for preventing and treating sepsis-induced ARDS.

3 October 2022 in Shock
Verified
Journal Article
Open access
YZYupeng Zhao
Yupeng Zhao
JZJinyuan Zhang
Jinyuan Zhang
HLHuihong Lu
Huihong Lu
YMYiliang Mao
Yiliang Mao
JQJiawen Qin
Jiawen Qin
LHLei Hou
Lei Hou
Our previous study confirmed that cardiopulmonary bypass (CPB) leads to acute lung injury (ALI) via inducing high-mobility group box 1 (HMGB1) release. Recent research showed that HMGB1 promotes pulmonary injury mainly via exosomes transport. Currently, alveolar epithelial cell (AEC) necroptosis has been demonstrated to be involved in ALI. However, it is unknown whether exosomal inflammatory cytokine HMGB1 promotes ALI by inducing AEC necroptosis, and its underlying mechanisms remain elusive. Here, a prospective cohort study was carried out, in which plasma samples from 21 CPB patients were isolated at four specific time points: pre-CPB, 2, 12, and 24 h after initiation of CPB. Plasma exosomes were extracted via ultra-high-speed centrifugation and cocultured with AEC cell line-A549 cells at increasing concentrations of 50, 100, and 150 μg/mL. Then, HMGB1 antagonist-Box A and mtDNA deficiency ethidium bromide (EtBr) were applied to explore the underlying role of exosomal HMGB1 and cytoplasm mitochondrial DNA in AEC. Western blot analysis showed that plasma exosomal HMGB1 expression gradually increased and peaked at 24 h after CPB. Twenty-four–hour treatment of CPB-derived exosomes at 150 μg/mL for 24 h could induce necroptosis by promoting mitochondrial fission and further elevating cytoplasm mtDNA levels in A549 cells, which was successfully blocked by Box A or EtBr. Most importantly, EtBr significantly inhibited cytoplasm mtDNA downstream guanosine monophosphate (GMP)-AMP synthase (cGAS)/stimulator of interferon gene (STING) signal pathway. Collectively, these data demonstrate that CPB-derived plasma exosomal HMGB1 contributes to AEC necroptosis through the mtDNA/cGAS/STING pathway.

2 July 2025 in Acta Biochimica et Biophysica Sinica
Verified
Journal Article
Open access
PDF file
YLYajing Liu
Yajing Liu
PYPengcheng Ye
Pengcheng Ye
CTCijun Tang
Cijun Tang
MJMeiru Jiang
Meiru Jiang
YSYiru Shen
Yiru Shen
YZYupeng Zhao
Yupeng Zhao
Accumulating evidence suggests that NLRP3-mediated alveolar macrophage (AM) pyroptosis and subsequent high mobility group box protein 1 (HMGB1) secretion play significant roles in the pathogenesis of acute respiratory distress syndrome (ARDS). Nrf2 has been shown to be individually involved in regulating pyroptosis. In this study, we investigate the ability of CDDO-imidazolide, a potent Nrf2 activator, to regulate AM pyroptosis and HMGB1 secretion in sepsis-associated ARDS, along with its underlying mechanism. The in vitro alveolar macrophage (AM) pyroptosis model, established by stimulating J774A.1 cells with LPS and ATP, was treated with CDDO-imidazolide or utilized Nrf2-knockout cells. The mice are intraperitoneally administered with CDDO-imidazolide before the in vivo sepsis-associated ARDS model is constructed via caecal ligation perforation and the Nrf2 inhibitor, ML385. In vitro studies reveal that the use of 3-MA to prohibit PINK1/Parkin-dependent mitophagy aggravates NLRP3-mediated pyroptosis and HMGB1 release in J774A.1 cells via LPS and ATP exposure. CDDO-imidazolide also significantly prevents NLRP3-mediated pyroptosis and HMGB1 release to increase PINK1/Parkin-dependent mitophagy, but these effects are not detected in Nrf2-knockout macrophages. Most importantly, CDDO-imidazolide significantly alleviates NLRP3 inflammasome protein expression in the lung tissues of septic mice and HMGB1 protein levels in the serum and bronchoalveolar lavage fluid (BALF), which can be reversed by ML385. Taken together, our results demonstrate that CDDO-imidazolide prominently protects the lungs by promoting Nrf2 activation and enhancing PINK1/Parkin mitophagy to inhibit AM pyroptosis and HMGB1 release. These findings provide novel insights for therapeutic strategies for sepsis-associated ARDS.

25 August 2023 in Research Square
Verified
Preprint
Open access
PDF file
YLYajing Liu
Yajing Liu
YZYupeng Zhao
Yupeng Zhao
CTCijun Tang
Cijun Tang
YSYiru Shen
Yiru Shen
CLChunzheng Liu
Chunzheng Liu
LHLei Hou
Lei Hou
Background NLRP3 inflammasome-mediated alveolar macrophage pyroptosis has been reported in promoting sepsis-related acute respiratory distress syndrome(ARDS).The nuclear factor E2-related factor (Nrf2) is involved in regulating NLRP3 inflammasome activation and pyroptosis. CDDO-imidazole (CDDO-Im), a forceful Nrf2 activator, in sepsis-related ARDS is lacking and its underling mechanism are still unclear. In this study, we aim to investigate the effect of CDDO-Im on lung protection and explored its underlying molecular mechanisms. Methods CDDO-Im (10, 50, 100nM) and 3-methyladenine (3-MA) were individually added into LPS and ATP stimulated alveolar macrophage cell line J774A.1 pyroptosis model. The Nrf2-/- and Nrf2+/+ mice were administered intraperitoneally with CDDO-Im (3µmol/kg body weight) before cecal ligation perforation surgery. Results In vitro studies we found that NLRP3 inflammasome activation mediated pyroptosis and slightly PINK1-meditaed mitophagy in alveolar macrophage cell line J774A.1 cells after LPS and ATP exposure. The autophagy inhibitor 3-methyladenine (3-MA) significantly aggravated NLRP3 inflammasome-mediated pyroptosis in J774A.1 cells by blocking PINK1-meditaed mitophagy. CDDO-Im obviously prevented NLRP3 inflammasome-mediated pyroptosis and HMGB1 release by Nrf2 pathway to enhance mitophagy in J774A.1 cells after LPS and ATP exposure. In vivo studies we found CDDO-Im significantly alleviated sepsis-related ARDS by blocking NLRP3 inflammasome activation via Nrf2 pathway to enhance mitophagy. Conclusion Our results demonstrate that CDDO-Im exhibits prominent lung protective role owing to its Nrf2 activation and mitophagy-enhancing properties, which provide a new insight into the strategies of ARDS clinical prevention and treatment.